TNFSF10 and familial dilated cardiomyopathy: The ZGJTSXF treatment could significantly reduce the ratios of p-PERK/PERK (Figure 5H), p-FoxO1/FoxO1 (Figure 5I), p-Bim/Bim (Figure 5J), PUMA/GAPDH (Figure 5K), TNFSF10/GAPDH (Figure 5L) that were upregulated in the DCM group (P<0.05, 0.01).